Aims: This study aimed to evaluate the variability of risk factors among patients with lower limb venous thrombosis, either Deep Vein Thrombosis (DVT) or Superficial Vein Thrombosis (SVT) in community patients with recent or current SARS-CoV-2 infection compared to a historical cohort.
Methods: We performed a historical retrospective analysis of all patients who presented to a primary health care unit and were diagnosed with DVT or SVT from January 2020 to December 2021. Historic controls were selected from January 2018 to December 2019. Demographic and clinical data were collected, including BMI, use of oral combined contraception, smoking status and date of COVID-19 infection diagnosis. Univariate analysis was performed for data assessment, including Chi-Square and ANOVA tests.
Results: Of the 8547 patients who attended a non-programmed consultation in the timeframe, seventy-nine patients (0.9%) were diagnosed with DVT (19) or SVT (60) and were included in the study. Their mean age was 57.3 ± 15.93 years, with a female-to-male ratio of 3.2 to 1. There was no significant association between COVID-19 and the development of DVT or SVT (p=0.151). However, there was a trend observed indicating a shift in the predominant gender in patients diagnosed with these conditions (85% females in 2018 versus 53.8% in 2021; p=0.077).
Conclusions: Outpatients seen by general practitioners during the pandemic of COVID-19 appear to present a trend towards an increased risk of combined DVT and SVT compared with patients of a historical cohort. Further studies are necessary to shed some light on this issue since robust evidence enables clinicians and policymakers to minimize venous thromboembolism risk in patients with SARS-CoV-2 infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.48729/pjctvs.310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Which is the safer option for adult patients between peripherally inserted central catheters and midline catheters: a meta-analysis.
Infect Control Hosp Epidemiol
November 2024
Department of Head and Neck Oncology Radiation Therapy, Jiangxi Cancer Hospital, Jiangxi, China.
Background: Peripherally inserted central catheters (PICC) and midline catheters (MC) are widely used for intravenous infusions in oncology and critically ill patients. However, controversy remains regarding which method is superior. This meta-analysis systematically compares the safety differences between these 2 methods of intravenous catheterization.
View Article and Find Full Text PDFThe subject of this guideline from the Institute of Family Medicine at the University of Zurich (IHAMZ) is the management of venous thrombosis. The review summarizes the current evidence and recommendations from international guidelines (1-6). The IHAMZ-guidelines focus on primary care, they also provide guidance on the coordination of general and specialist medical care as well as on the transition between outpatient and hospital care taking into account the special features of the Swiss healthcare system.
View Article and Find Full Text PDFCurrent evidence on the effectiveness and safety of oral anticoagulants in superficial venous thrombosis: a systematic review and meta-analysis.
Int Angiol
October 2024
Department of Vascular Surgery, Sint-Andriesziekenhuis Tielt, Belgium.
Article Synopsis
- The study investigates the effectiveness and safety of oral anticoagulants (OACs), particularly rivaroxaban, as a treatment for superficial venous thrombosis (SVT), providing a more convenient alternative to traditional parenteral injections.
- A systematic review was conducted following PRISMA guidelines, analyzing six studies that involved adult patients treated with OACs and reporting outcomes related to efficacy and safety.
- Results show that OACs, especially rivaroxaban, demonstrated low rates of deep vein thrombosis (DVT), SVT extension, recurrence, and bleeding, suggesting they are a viable treatment option for SVT, although more extensive research is needed to solidify these conclusions.*
Risk of venous thromboembolism after discontinuing prophylactic or therapeutic anticoagulation in patients with haematologic malignancies because of thrombocytopenia.
J Thromb Thrombolysis
October 2024
Clinic of Vascular Medicine, HELIOS Klinik Krefeld, Lutherplatz 40, 47805, Krefeld, Germany.
Although the rates of thrombocytopenia in patients with hematologic malignancies are well known, clinical reports of patients with haematological malignancies presenting with thrombocytopenia who developed venous thromboembolism (VTE) are rare. Defining the risk of VTE in patients with hematologic malignancies in whom anticoagulation is discontinued could help to individualize concepts of anticoagulation. We performed a retrospective analysis of medical records of patients with hematologic malignancies and thrombocytopenia grade 3 (25 × 10/L to < 50 × 10/L) or more severe in 2019-2022 in the Department of Haemato-Oncology at HELIOS Klinikum Krefeld.
View Article and Find Full Text PDFCurrent Diagnostic and Therapeutic Challenges in Superficial Venous Thrombosis.
Medicina (Kaunas)
September 2024
Dr. Carol Davila University Central Military Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Calea Plevnei 134, 010825 Bucharest, Romania.
Article Synopsis
- * Risk factors for SVT include varicose veins, but other underlying issues like cancers or blood disorders may be present, especially in non-varicose veins.
- * Diagnosis often requires duplex ultrasound (DUS) to determine the clot's characteristics, and treatment usually focuses on medical management, including anticoagulation and symptom relief, with more invasive approaches reserved for severe cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!